On the stock market since 2019, it operates in the world of health and science. It has 115 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash-and-debt balance is neither shiny nor alarming.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.77. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 5/100.
The growth engine is running at low revs right now. Report-card grade: 8/100.
On our five-subject report card, CELU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CELU is a high-risk stock — not yet profitable, and its future rides on its product catching on.